NasdaqGS:ALMSPharmaceuticals
How Investors Are Reacting To Alumis (ALMS) Psoriasis Drug’s Strong Phase 3 Data And Safety Profile
Alumis Inc. recently reported Phase 3 ONWARD1 and ONWARD2 data showing its oral TYK2 inhibitor envudeucitinib produced high rates of robust, durable skin clearance and quality-of-life improvements in adults with moderate-to-severe plaque psoriasis through Week 24, with a generally well-tolerated safety profile.
An interesting aspect for investors is envudeucitinib’s maximal 24-hour TYK2 inhibition without fasting requirements, aiming to balance efficacy, convenience, and selective immune...